November 20 (SeeNews) - North Macedonia-based drug maker Replek [MSE:REPL] said that its consolidated net profit remained unchanged year-on-year at 85.4 million denars ($1.5 million/1.4 million euro) in the first nine months of 2019.
Replek's operating revenue rose 5% to 761.5 million denars in the January-September period of 2019, the company said in an interim financial statement.
Domestic sales added 7% to 318.2 million denars, while sales abroad edged up 2% to 423.9 million denars.
The company's operating expenses were 7% higher on the year at 672.9 million denars in the review period.
(1 euro = 61.50 denars)